NCT06514261 - Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

September 16, 2026

Study Completion Date

September 16, 2026

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine

Given IV or SC

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Buccal Swab

Undergo buccal swab

DRUG

Iadademstat

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (4)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

45219

RECRUITING

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati

92612

RECRUITING

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH